DRD3 and Hyperammonemia: From a collection of 182 small molecules consisting of compounds approved or under investigation for hyperammonemia treatment (e.g. Sodium benzoate (NaB), NaPB, L‐ornithine, 5‐azacytidine and resveratrol) 6, 20, 21, 22, 23, 24, dopamine D3 receptor inhibitor, mTOR and TNF pathway activator/inhibitor, 23 small molecules increased the signal intensity, while 21 repressed the fluorescence intensity significantly.